909-19 - IDENTIFICATION OF STAGE B HEART FAILURE IN A HIGH-RISK MEDICARE POPULATION IN A FULLY DECENTRALIZED, LARGE-SCALE INTEGRATED CARDIOLOGY PROGRAM

View session detail

Author Block: Jana M. Goldberg, Pei-Chun McGregor, Halary Patch, Jeffrey Wessler, Heartbeat Health, New York, NY, USA
Background: Heart failure is estimated to grow to 8 million Americans by 2030. Evidence suggests that early identification and management of asymptomatic stage B HF helps to mitigate progression to stage C/D. There is little existing data regarding heart failure identification and management opportunities through innovative care pathways in a high risk, value-based primary care environment.
Methods: A large-scale, decentralized cardiology program was implemented to support a Medicare population. Echocardiograms were performed for patients who were elevated risk for stage B heart failure (age > 60y and 2+ risk factors including hypertension, DM, CVD, obesity, smoking, HL, cardiotoxins, family history/genetic cardiomyopathy, with elevated BNP ≥ 50 ng/L).
Results: Between April 2022 and August 2024, 1,812 patients received echocardiograms with an average age 73 years. Of these, 71% had evidence of at least stage B HF and 17.8% had evidence of moderate to severe valve disease, among other high risk findings (Table 1). Patients with stage B or C HF (based on symptoms) were then co-managed by primary care and cardiology via televisits and eConsults based on stage.
Conclusion: Implementation of a decentralized stage B HF identification program in a high-risk Medicare cohort demonstrates a high burden of disease in this population with clear opportunities for management and improved outcomes.